🔎 Trials Near Me

Dachaigh › Leukemia › Tennessee

Sgrùdaidhean clionaigeach Leukemia ann an Tennessee

Tha 14 sgrùdaidhean airson Leukemia a’ lorg phàirtichean aig làraichean ann an Tennessee.

Bailtean ann an Tennessee

Teacsa sgrùdaidh oifigeil (Beurla)

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 12, Nashville
A’ fastadhÌre 3
Aoisean 18 gu 71 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07504458

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

  • St. Jude Children's Research Hospital, Memphis
A’ fastadhÌre 1
Suas gu aois 25 · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT06810583

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07284433

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Baptist Clinical Research Institute, Memphis
  • Tennessee Oncology, Nashville
  • TriStar Centennial Medical Center, Nashville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Vanderbilt University Medical Center, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT06001788

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • TriStar BMT, Nashville
A’ fastadhÌre 1/2
Aoisean 13 gu 90 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06533579

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Vanderbilt University, Ingram Cancer Center, Nashville
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Iuch 2026 · NCT07216443

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Vanderbilt University Medical Center, Nashville
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Gibl 2026 · NCT04256317

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Baptist Clinical Research Institute, Memphis
A’ fastadhÌre 1/2
Aoisean 12 gu 95 · Gach gnè · Air ùrachadh 15 Gibl 2026 · NCT04329728

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • TriStar Bone Marrow Transplant, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Màrt 2026 · NCT05735184

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist (BHMCC), Memphis
  • Vanderbilt-Ingram Cancer Center, Nashville
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 agus nas sine · Gach gnè · Air ùrachadh 20 Faoi 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Memphis
  • Massive Bio SYNERGY-AI site, Nashville
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • Sarah Cannon Research Institute, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2025 · NCT06501196

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • TriStar Bone Marrow Transplant, Nashville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Samh 2024 · NCT06034275

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.